Intangible Assets, net

The Company’s definite-lived intangible assets as of March 31, 2020 and December 31, 2019 consisted of the following:



	March 31, 2020			December 31, 2019
Customer relationships	$	52,000		$	52,000
Developed technologies	32,000			32,000
Trade name	3,000			3,000
	87,000			87,000
Less: Accumulated amortization	(37,162		)	(35,152		)
Intangible assets, net	$	49,838		$	51,848

Amortization of definite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or the pattern in which economic benefits are consumed, if reliably determinable. The Company reviews its definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization expense from continuing operations for the three months ended March 31, 2020 and 2019 was $2,010 and $2,287, respectively.

During the three months ended June 30, 2019, the Company identified an indicator of impairment with respect to the NantHealth Labs, Inc. definite-lived intangible assets given the decline in sales and the Company's decision to cease commercial sales of its liquid biopsy test offering to focus on performing a study to measure the clinical utility of the AR-V7 analyte for informing treatment in patients with castration-resistant prostate cancer. Although the Company will continue this study while also pursuing other strategically aligned clinical studies that support its liquid biopsy platform, the Company determined that the assets were not recoverable given the significant amount of costs required to further build evidence of clinical utility while also ceasing commercial sales of the Liquid GPS product. Therefore, the Company fully impaired the intangible assets as of June 30, 2019 and recorded an impairment loss of $3,977 within operating expenses.

The estimated future amortization expense over the next five years and thereafter for the intangible assets that exist as of March 31, 2020 is as follows:



	Amounts
Remainder of 2020	$	6,029
2021	8,038
2022	8,038
2023	3,467
2024	3,467
2025	3,467
Thereafter	17,332
Total future intangible amortization expense	$	49,838